Clinical Trial Update: AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update announcing ongoing Phase 1/2 study of AMT-260 gene therapy for adults with unilateral refractory mesial temporal lobe epilepsy (recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesial Temporal Lobe Epilepsy

Drugs mentioned

• AMT-260 (AMT-260 gene therapy)

Snippet

Sponsor: UniQure Biopharma B.V. | Conditions: Mesial Temporal Lobe Epilepsy | Phase 1, Phase 2 | Status: RECRUITING